Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ TCEAL1 Monoclonal Antibody (OTI2G10)
Mouse Monoclonal Antibody
Supplier: Invitrogen™ MA526910
Description
TCEAL1 Monoclonal Antibody for Western Blot, IHC (P)
TCEAL1 (transcription elongation factor A (SII) protein 3), also known as p21, SIIR or pp21, is a member of the TFS-II family. Transcription elongation factors of the TFS-II family are responsible for releasing RNA polymerase II (Pol II) from transcriptional arrest. DNA arresting sites can result in locked ternary complexes if elongating RNA polymerases are trapped. Transcription elongation factors function to activate the intrinsic RNA cleavage activity of RNA polymerases. This allows the RNA polymerase to cleave the nascent transcript, thereby forming a new 3'-terminus to resume elongation. TCEAL1 is a 157 amino acid nuclear protein that is ubiquitously expressed. TCEAL1 may exert its effects via protein-protein interactions with other transcriptional regulators rather than via direct binding of DNA.
Specifications
TCEAL1 | |
Monoclonal | |
1 mg/mL | |
PBS with 1% BSA, 50% glycerol and 0.02% sodium azide; pH 7.3 | |
Q15170 | |
TCEAL1 | |
Full length human recombinant protein of TCEAL1 produced in E.coli. | |
100 μL | |
Primary | |
Human | |
Antibody | |
IgG1 |
Immunohistochemistry (Paraffin), Western Blot | |
OTI2G10 | |
Unconjugated | |
TCEAL1 | |
0610011M09Rik; BC011290; Nuclear phosphoprotein p21/SIIR; P21; pp21; SIIR; TCEAL1; TCEA-like protein 1; transcription elongation factor A (SII)-like 1; transcription elongation factor A like 1; transcription elongation factor A protein-like 1; Transcription elongation factor S-II protein-like 1; WEX9 | |
Mouse | |
Affinity chromatography | |
RUO | |
9338 | |
-20°C, Avoid Freeze/Thaw Cycles | |
Liquid |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction